Aspen Pharmacare Holdings Limited

JSE:APN Rapporto sulle azioni

Cap. di mercato: R80.0b

Aspen Pharmacare Holdings Performance dei guadagni passati

Il passato criteri di controllo 1/6

Aspen Pharmacare Holdings ha registrato una crescita degli utili a un tasso medio annuo di 16.8%, mentre il settore Pharmaceuticals ha registrato utili in crescita a un tasso medio annuo di 15.1%. I ricavi sono stati in crescita a un tasso medio annuo di 4.6%. Il ritorno sul capitale proprio di Aspen Pharmacare Holdings è 5.2% e ha margini netti di 9.9%.

Informazioni chiave

16.8%

Tasso di crescita degli utili

17.4%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore12.4%
Tasso di crescita dei ricavi4.6%
Rendimento del capitale proprio5.2%
Margine netto9.9%
Ultimo aggiornamento sui guadagni30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Aspen Pharmacare Holdings' (JSE:APN) Conservative Accounting Might Explain Soft Earnings

Oct 10
Aspen Pharmacare Holdings' (JSE:APN) Conservative Accounting Might Explain Soft Earnings

Recent updates

Aspen Pharmacare Holdings' (JSE:APN) Conservative Accounting Might Explain Soft Earnings

Oct 10
Aspen Pharmacare Holdings' (JSE:APN) Conservative Accounting Might Explain Soft Earnings

Here's Why Aspen Pharmacare Holdings (JSE:APN) Has A Meaningful Debt Burden

Oct 01
Here's Why Aspen Pharmacare Holdings (JSE:APN) Has A Meaningful Debt Burden

Aspen Pharmacare Holdings (JSE:APN) Has Announced That It Will Be Increasing Its Dividend To ZAR3.59

Sep 10
Aspen Pharmacare Holdings (JSE:APN) Has Announced That It Will Be Increasing Its Dividend To ZAR3.59

We Think Aspen Pharmacare Holdings (JSE:APN) Can Stay On Top Of Its Debt

May 08
We Think Aspen Pharmacare Holdings (JSE:APN) Can Stay On Top Of Its Debt

Aspen Pharmacare Holdings Limited's (JSE:APN) P/E Still Appears To Be Reasonable

Mar 05
Aspen Pharmacare Holdings Limited's (JSE:APN) P/E Still Appears To Be Reasonable

Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet

Dec 22
Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet

Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment

Dec 01
Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment

Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet

Mar 31
Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet

With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Makes An Interesting Case

Jan 11
With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Makes An Interesting Case

These 4 Measures Indicate That Aspen Pharmacare Holdings (JSE:APN) Is Using Debt Reasonably Well

Oct 22
These 4 Measures Indicate That Aspen Pharmacare Holdings (JSE:APN) Is Using Debt Reasonably Well

We Ran A Stock Scan For Earnings Growth And Aspen Pharmacare Holdings (JSE:APN) Passed With Ease

Oct 06
We Ran A Stock Scan For Earnings Growth And Aspen Pharmacare Holdings (JSE:APN) Passed With Ease

Aspen Pharmacare Holdings' (JSE:APN) Upcoming Dividend Will Be Larger Than Last Year's

Sep 21
Aspen Pharmacare Holdings' (JSE:APN) Upcoming Dividend Will Be Larger Than Last Year's

Aspen Pharmacare Holdings Limited (JSE:APN) Analysts Just Cut Their EPS Forecasts Substantially

Sep 08
Aspen Pharmacare Holdings Limited (JSE:APN) Analysts Just Cut Their EPS Forecasts Substantially

Aspen Pharmacare Holdings (JSE:APN) Is Increasing Its Dividend To ZAR3.26

Sep 07
Aspen Pharmacare Holdings (JSE:APN) Is Increasing Its Dividend To ZAR3.26

Here's Why We Think Aspen Pharmacare Holdings (JSE:APN) Might Deserve Your Attention Today

Jun 15
Here's Why We Think Aspen Pharmacare Holdings (JSE:APN) Might Deserve Your Attention Today

Aspen Pharmacare Holdings (JSE:APN) Seems To Use Debt Quite Sensibly

Apr 02
Aspen Pharmacare Holdings (JSE:APN) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Is Interesting

Mar 16
With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Is Interesting

An Intrinsic Calculation For Aspen Pharmacare Holdings Limited (JSE:APN) Suggests It's 33% Undervalued

Mar 02
An Intrinsic Calculation For Aspen Pharmacare Holdings Limited (JSE:APN) Suggests It's 33% Undervalued

Is Aspen Pharmacare Holdings (JSE:APN) A Risky Investment?

Dec 23
Is Aspen Pharmacare Holdings (JSE:APN) A Risky Investment?

Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation

Dec 02
Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation

We Think Aspen Pharmacare Holdings' (JSE:APN) Robust Earnings Are Conservative

Oct 11
We Think Aspen Pharmacare Holdings' (JSE:APN) Robust Earnings Are Conservative

After Leaping 42% Aspen Pharmacare Holdings Limited (JSE:APN) Shares Are Not Flying Under The Radar

Sep 30
After Leaping 42% Aspen Pharmacare Holdings Limited (JSE:APN) Shares Are Not Flying Under The Radar

Aspen Pharmacare Holdings Limited (JSE:APN) Looks Just Right With A 42% Price Jump

Sep 30
Aspen Pharmacare Holdings Limited (JSE:APN) Looks Just Right With A 42% Price Jump

Ripartizione dei ricavi e delle spese

Come Aspen Pharmacare Holdings guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

JSE:APN Ricavi, spese e utili (ZAR Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Jun 2444,7064,40410,1000
31 Mar 2443,7034,6369,9360
31 Dec 2342,7004,8689,7710
30 Sep 2341,7055,0489,5830
30 Jun 2340,7095,2289,3940
31 Mar 2339,5425,5159,1270
31 Dec 2238,3755,8028,8590
30 Sep 2238,4916,1458,6920
30 Jun 2238,6066,4888,5250
31 Mar 2238,5606,1858,6560
31 Dec 2138,5145,8818,7960
30 Sep 2138,1405,3408,9550
30 Jun 2137,7664,7989,1140
31 Mar 2135,7603,9548,8660
31 Dec 2036,3083,7829,0750
30 Sep 2034,9843,5818,9760
30 Jun 2033,6593,3808,8760
31 Mar 2039,9273,2729,9880
31 Dec 1933,6208708,9540
30 Sep 1934,5671,2759,1540
30 Jun 1935,5141,6799,3540
31 Mar 1936,8803,3509,6120
31 Dec 1836,6834,8909,5750
30 Sep 1837,4995,2569,5730
30 Jun 1838,3145,6219,5700
31 Mar 1839,6185,6829,6780
31 Dec 1740,9225,7439,7860
30 Sep 1741,0685,4369,6360
30 Jun 1741,2135,1289,4850
31 Mar 1739,5574,4149,2930
31 Dec 1637,9003,7009,1000
30 Sep 1636,7504,0008,8500
30 Jun 1635,6004,3008,6000
31 Mar 1635,5835,2208,5530
31 Dec 1535,5676,1408,5060
30 Sep 1535,8335,6708,5030
30 Jun 1536,1005,2008,5000
31 Mar 1535,8365,3698,0710
31 Dec 1435,5725,5377,6410
30 Sep 1432,5445,2726,8470
30 Jun 1429,5155,0086,0540
31 Mar 1425,9014,3885,2000
31 Dec 1322,2873,7684,3460

Guadagni di qualità: APN ha un grande una tantum perdita di ZAR1.9B che ha avuto un impatto sui suoi ultimi 12 mesi di risultati finanziari pari a 30th June, 2024.

Margine di profitto in crescita: Gli attuali margini di profitto netti di APN (9.9%) sono inferiori rispetto allo scorso anno (12.8%).


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di APN sono cresciuti del 16.8% all'anno negli ultimi 5 anni.

Accelerare la crescita: APN ha avuto una crescita negativa degli utili nell'ultimo anno, quindi non può essere confrontata con la sua media quinquennale.

Guadagni vs Settore: APN ha avuto una crescita negativa degli utili ( -15.8% ) nell'ultimo anno, rendendo difficile il confronto con la media del settore Pharmaceuticals ( 16% ).


Rendimento del capitale proprio

ROE elevato: Il Return on Equity ( 5.2% ) di APN è considerato basso.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate